The importance of defining which Janus kinases are activated in giant cell arteritis

Systemic vasculitis: one year in review 2024

“…The authors observed a 70% remission rate in the SEK group compared to 20% in placebo group, with no significant safety concerns (39). Regarding Janus kinase (JAK) inhibitors, an ongoing randomised phase 3 study of upadacitinib in GCA (ClinicalTrials.gov; NCT03725202) is currently in the recruitment stage (40). Additionally, results from a retrospective Swedish case series involving 15 GCA patients treated with baricitinib and tofacitinib are now available (41).…”